Last reviewed · How we verify

NCT03692416

The Effect of Some Drugs Used in Treatment of Vasculitis on the Complement System in Children

Status unknown Phase 3 Last updated 15 February 2021
What this trial tests

Phase 3 trial testing Ibuprofen in Vasculitis in 70 participants. Status unknown.

Timeline
11 November 2018
Primary endpoint
11 November 2021
11 May 2022

Quick facts

Lead sponsorAssiut University
PhasePhase 3
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment70
Start date11 November 2018
Primary completion11 November 2021
Estimated completion11 May 2022
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Assiut University

Who can join

Adults 1 Month to 17, any sex, with Vasculitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Vasculitis denotes affection of small to medium sized vessels by polyangitis. Antineutrophil cytoplasmic antibodies (ANCA) are immunoglobulin G (IgG) autoantibodies directed against constituents of neutrophil granules leading to neutrophil degeneration which results in cell apoptosis known as "Natoptosis" (NaTosis) of the cells. These lead to vessel endothelial cell damage. So that, ANCA formation seems to be the basic reaction in vasculitis. Complement activation at C3 and C4 was thought to be involved in renal damage ANCA associated vasculitis (AAV).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Ibuprofen

Trials testing the same drug.

Other recruiting trials for Vasculitis

Currently open trials in the same condition.

Other Assiut University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03692416.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing